

Preface

THE TITLE OF THIS BOOK COULD HAVE BEEN “The RNA World, 4th edition,” because it is very much the descendent of three previous volumes published by Cold Spring Harbor Laboratory (CSHL) Press. Instead, we’ve chosen “RNA Worlds” to reflect the book’s dual purpose. On the one hand, the volume covers the exciting diversity of form and function of RNA in the present day world, including RNA functions that have been discovered only recently and are still emerging. On the other hand, the volume maintains a major focus on the ancient RNA world that is thought to have predated genetically encoded proteins, DNA, and organisms we know about. As documented here, evidence for the reality of such a primordial role for RNA is increasing, although challenges remain in demonstrating model RNA-based replicases and in uncovering feasible origins of precursors for RNA synthesis. Nevertheless the plasticity of RNA stemming from its 2′ hydroxyl group and single-stranded nature, which permits diverse folding in contrast to its storage molecule cousin, DNA, continues to fascinate.

Even as we see health and economic benefits of biological research, including RNA research, pursuit of intellectual curiosity remains fundamentally important for the human psyche as it was for explorers in previous eras. Curiosity about our origins seems particularly deep-seated, as reflected by the complex tapestry of explanations in the religious heritages of diverse societies. But the scientific explanations of life’s origins seem more ennobling to us than, for instance, the idea of the original human female being derived from a rib of a man.

The evidence is overwhelming that not only all humans but all known life on earth had a common origin. This would not be a surprise to Darwin who wrote in his “Origin of Species” book one and a half centuries ago that “probably all organic beings which have ever lived on this earth have descended from some one primordial form”. To what extent these conclusions have been providing a bulwark against the intolerance of fundamentalist beliefs is, of course, part of a “well-worn” debate.

These considerations contribute to the broad interest in theories and experiments concerning a primordial RNA world. How best to focus interest on the key roles that RNA played in the origins of life and continues to play in

present day species diversity and function? It is crucial to continue the present research directions in biology to reveal the bonanza yet in store and to encourage its distillation and dissemination to a wider audience.

Even the pioneers of the RNA world concept did not foresee that ribozymes had survived to the present day. Is it conceivable that some RNA-based organisms currently exist on our planet? After all, without ribosomes, such an “organism” may be even smaller than organisms that rely on protein synthesis. Such an organism might be uniquely present in some minute deep-rock niches, and maybe in environments that could not support predatory DNA-based organisms. Such a ribo-organism might even have evolved strategies to resist predation. While microorganisms are now known to live deeper in the earth and in more places than previously appreciated, the possibility of RNA-based organisms whose ancestor arose after the general advent of protein-based life does not seem to have been widely considered. Search of stable shales with appropriate pore sizes would likely yield new organisms with an unquantifiable possibility of the discovery of RNA-based organisms that would even require modification of the statement above about common ancestry. As referenced in the chapter by Benner and colleagues, this is just one of the possibilities for radically different life on earth whose potential existence merits investigation. Such a project would be much cheaper than the quest to find life on Mars and, if successful, just as wonderful scientifically.

Since the third edition of “The RNA World” book, a key pioneer of RNA world studies and author in three previous editions of the book, Leslie Orgel, has passed away. We will not forget his rigorous approach to origin-of-life experiments and his warm humor.

We thank Richard Sever and John Inglis of CSHL Press for wise advice and continuing support. It is a pleasure also to acknowledge the care and understanding of the project coordinator at CSHL, Inez Sialiano, in making this book a reality, and Susan Roberts for help with the cover graphics.

J.F. ATKINS
R.F. GESTELAND
T.R. CECH

Index

A

- Adenine, abiotic synthesis, 33
S-Adenosylhomocysteine (SAH), riboswitch ligand, 69–71, 85
S-Adenosylmethionine (SAM)
 riboswitch ligand, 69–71
 tandem riboswitches, 72–74
Adenovirus, noncoding RNA function, 166, 169
AFM. *See* Atomic force microscopy
Age-related macular degeneration (ARMD),
 aptamer therapy, 334–335
Ago. *See* Argonaute
Alanyl nucleic acid (ANA)
 abiotic synthesis, 37
 polymer structure, 36
Alu RNA, RNA polymerase II loading mediation, 285–287
6-Amino-5-nitropyridin-2-one, six letter polymerase chain
 reaction, 15–16
ANA. *See* Alanyl nucleic acid
Ancient RNA
 conservation and persistence, 45
 evidence, 44–45
 persistence, 45
Anisomycin, peptidyl transferase reaction inhibition,
 131–132
Aptamer. *See* SELEX; SOMAmers
Arabinoside, abiotic synthesis, 33–34
ArcZ, small RNA regulator function, 219–220
Argonaute (Ago)
 ancestral function, 250–251
 phylogenetic analysis in three clades, 244–245
 Piwi, 250, 258
 RNA binding modes, 247–248
 RNA interference role, 244, 257–258
 small RNA-guided cleavage, 248–250
 structure and function, 245–247
ARMD. *See* Age-related macular degeneration
Assemble program, interactive molecular modeling,
 314–315, 317
Atomic composition, CHNOPS consistency, 45
Atomic force microscopy (AFM), RNA folding studies,
 323–324, 328
Azithromycin, peptidyl transferase reaction inhibition, 131–132

outer membrane protein synthesis repression, 219
overview, 219–220
transcription factor synthesis modulation, 219
Hfq function, 218
Hfq-independent base pairing, 218–219
mechanisms, 217–219
outcomes, 217–218
evolution
 capture of random transcription for purpose of
 regulation, 226
 recent evolution
 conserved gene neighborhood, 225
 conserved regulation, 225
 gene duplication, 225
 horizontal transfer, 225–226
 target-imposed constraints, 225
 sRNA-mRNA connections, 226
 sRNA-tRNA connections, 226
functional overview, 216
mimics in regulation, 221–222
mRNA dual function, 221
prospects for study, 227
protein activity modulation
 CsrB, 223
 discovery, 223
 6S RNA, 222–223
riboswitches, 221
tmRNA intrinsic functions, 223–224
Bayes's theorem, RNA world applicability, 45
Borate, premetabolic cycle, 14–15
Brr2
 small nuclear ribonucleoprotein structure,
 193–194
 spliceosome function, 191

C

B

- Bacterial small RNA regulators (sRNAs). *See also* CRISPRs
 abundance of types, 216
 antisense small RNA regulators, 217
 base pairing with limited complementarity
 functions

- Cas. *See* CRISPRs
CCND1
 histone modification mediation, 284–285
 signal sensing, 288
Cellular life
 membranes as compartment boundaries, 52–53
 phosphoramidate nucleic acids, 57–59
 protocell
 assembly, 59
 encapsulated templated replication, 59–60
 prospects for complete model, 60–61
 RNA-catalyzed RNA replication, 56–57
 vesicle division pathways, 55–56
 vesicle growth pathways, 53–55

chbBC, small RNA regulator function, 221–222
Chirality, early life, 35
Chloramphenicol, peptidyl transferase reaction inhibition, 131
Chromatin. *See* Heterochromatin
Cid12, heterochromatic RNA interference at fission yeast centromeres, 259
Class I ligase ribozyme. *See* RNA ligase ribozyme
Clusters of regularly interspersed short palindromic repeats. *See* CRISPRs
CMT3, heterochromatic RNA interference, 262
CMV. *See* Cytomegalovirus
Contemporary RNA world, overview, 3–4
COSMIC LOPER, overview, 48
CRISPRs
 Cas protein functions, 235
 examples, 233
 functional overview, 232
 loci and Cas genes, 232, 234
 mechanism of action
 integration of new spacers, 235–236
 target interference, 237–238
 transcription and processing, 236–237
 prospects for study, 240
 RNA interference homology, 238–240
CsrB, small RNA regulator function, 223
Ctcf, X-chromosome inactivation role, 271
CyaR, small RNA regulator function, 226
Cytomegalovirus (CMV), noncoding RNA, 174

D

DDM1, heterochromatic RNA interference, 262
DEAD-box proteins
 group II intron association, 113
Ded1p, helicase mechanism studies, 328
DHFR. *See* Dihydrofolate reductase
Dicer, RNA interference role, 257–258
Dihydrofolate reductase (DHFR), long noncoding RNA regulation, 287–288
DsrA, small RNA regulator function, 219–220
Duplicator RNA, origins of ribosomal decoding site, 148–150

E

EBER. *See* Epstein-Barr virus-encoded RNA
eIF4A, helicase mechanism studies, 328
Electron density map, fitting of atomic models, 314
Elongation factors
 homology between species, 10–11
 temperature optimum in eubacteria, 11
Elongation factors, structure and function, 136–137
Epstein-Barr virus-encoded RNA (EBER)
 discovery, 174–175
 functions, 168, 170
 microRNAs, 173–174
 ribonucleoprotein complexes, 168, 170
 transcripts, 166, 168

Eri1, silencing on chromosome arms, 261
Error threshold, RNA replicase, 26–27
Erythromycin, peptidyl transferase reaction inhibition, 131
Evf2, histone modification mediation, 283–284

F

FAD
 continuity with RNA world, 47–48
 initial darwinian ancestor modern descendant, 46
fbp1+, RNA polymerase II loading mediation, 287
Fidelity
 early RNA replicase, 26–27
 translation, 133
Flavin mononucleotide (FMN), riboswitch ligand, 67–68, 85
Fluorescence resonance energy transfer (FRET)
 folding pathways of purine riboswitch aptamer, 83–84
 single-molecule studies of RNA reactions, 324–329
 vesicle growth studies, 53–54
FMN. *See* Flavin mononucleotide
Folding. *See* Modules, RNA; Secondary structure, RNA; Tertiary structure, RNA
Frameshifting. *See* Ribosome

G

GlcN6P. *See* Glucosamine-6-phosphate
glmS ribozyme
 catalytic mechanism, 98–99
 glucosamine-6-phosphate cofactor, 98–99
 structural overview, 95–96
GlmY, small RNA regulator function, 221–222
Glucosamine-6-phosphate (GlcN6P)
 glmS ribozyme cofactor, 98–99
 riboswitch ligand, 66–67
Glyceraldehyde-2-phosphate, abiotic synthesis, 33
Glycoaldehyde phosphate, abiotic synthesis, 33
Glycol nucleic acid (GNA)
 abiotic synthesis, 37
 polymer structure, 36
GNA. *See* Glycol nucleic acid
Group II intron
 associated proteins
 DEAD-box proteins, 113
 intron-encoded protein component, 104, 106–108, 111–112
 LtrA, 112
 recruitment, 113
 catalytic mechanism, 108–109
 degenerate intron splicing, 106
 evolution, 116–117
 lineages, 108
 mobility
 DNA target site recognition, 115
 retrohoming
 mechanisms, 115
 reverse splicing into DNA, 113–115
 retrotransposition into new sites, 115–116
 targetrons, 116

phylogenetic distribution, 104
RNA structure, 104–106
three-dimensional structure, 109–111
trans-splicing, 106
twintron formation, 106

H

Hairpin ribozyme
catalytic mechanism, 96–97
fluorescence resonance energy transfer studies, 324–325
RNase H homology, 97
structural overview, 95–96

Hammerhead ribozyme
catalytic mechanism, 98
structural overview, 95–96, 98

HDV ribozyme. *See* Hepatitis delta virus ribozyme

Hepatitis delta virus (HDV) ribozyme, structural overview, 95–96, 99–100

Herpes simplex virus-1 (HSV-1), noncoding RNA, 174

Herpesvirus saimiri U RNA (HSUR)
function, 171
structure, 170–171
transcripts, 170–171

Heterochromatin
definition, 256
histone modification mediation by long noncoding RNA
CCND1, 284–285
Evf2, 283–284
HOTAIR, 285
SRA, 283
histone modifications, 256–257
position effect variegation, 256
RNA interference
filamentous fungi, 262–263
fission yeast centromeres, 258–261
silencing on chromosome arms, 261–262

Hfq, small RNA regulator base pairing with limited complementarity role, 218

Histones. *See* Heterochromatin

HIV. *See* Human immunodeficiency virus

HOTAIR, histone modification mediation, 285

HOX genes, *HOTAIR* regulation, 285

Hrr1, heterochromatic RNA interference at fission yeast centromeres, 259

HSUR. *See* Herpesvirus saimiri U RNA

HSV-1. *See* Herpes simplex virus-1

Human immunodeficiency virus (HIV), reverse transcriptase
RNA-binding studies, 326–328

Hydrolysis, susceptibility of RNA bonds, 12

I

IAPV. *See* Israeli acute paralysis virus

IDA. *See* Initial darwinian ancestor

Imidazo(1,2-c)pyrimidin-5(1H)-one, six letter polymerase chain reaction, 15–16

Initial darwinian ancestor (IDA)
AMP-containing enzymatic cofactors as modern descendants, 45–46
origin of life context, 47
time vantage, 44

Initiation factors, deletion studies, 142

Internal transesterification reaction, small self-cleaving ribozymes, 94–95

Internally transcribed spacer (ITS), phylogenetic reconstruction, 303

Intron-encoded protein. *See* Group II intron

Israeli acute paralysis virus (IAPV), RNA interference targeting, 350

ITS. *See* Internally transcribed spacer

K

Kaposi's sarcoma-associated herpesvirus (KSHV)
microRNA, 173
PAN RNA function, 171–172

Kasugamycin, resistance mechanisms, 142

Khps1, DNA methylation mediation, 285

KSHV. *See* Kaposi's sarcoma-associated herpesvirus

L

L1 ligase. *See* RNA ligase ribozyme

L22, Epstein-Barr virus-encoded RNA binding, 170

La, Epstein-Barr virus-encoded RNA binding, 168

Last universal common ancestor (LUCA), RNA fragments, 11

Leakage, premetabolic cycle, 15

Life. *See also* Cellular life
definition, 8
origin study approaches, 8–9
RNA-first view on origin
nonenzymatic replication of RNA, 24–25
nucleotide biosynthesis, 31–32
polynucleotide abiotic synthesis, 22–24
RNA replicase, 25–31
RNA-later view on origin
alternate genetic systems, 35–38
nucleotide synthesis, 32–35

Linezolid, peptidyl transferase reaction inhibition, 131

Long noncoding RNA. *See also* Polycomb proteins;
X-chromosome inactivation
advantages in function
sequence specificity, 275–276
transcription site localization, 275
cell structure integrity role, 288
classification, 280
expression regulation, 281
functional overview, 280
processing, 281–282
promoter-associated RNA functions, 287–288
prospects for study, 288
protein complex recruitment, 282–283
signal sensing, 288
strandedness, 280

Long noncoding RNA (*Continued*)

- subcellular localization, 280–281
- transcriptional boundary marking, 288
- transcriptional regulation mechanisms
 - DNA methylation, 285
 - histone modification, 283–285
 - RNA polymerase II loading, 285–287
 - transcription factors, 287
 - transcription interference, 287
- LtrA, group II intron association, 112
- LUCA. *See* Last universal common ancestor

M

- M1CB, herpesvirus targeting, 173
- Macugen, historical perspective, 334
- Malaria, RNA interference targeting, 350
- Manip* program, interactive molecular modeling, 314
- Meiotic silencing of unpaired DNA (MSUD),
 - RNA interference pathway, 251
- Membrane
 - compartment boundaries, 52–53
 - vesicles
 - division pathways, 55–56
 - growth pathways, 53–55
- 1-Methyl-adenine derivatives, polymerization, 24
- 2-Methylimidazole derivatives, polymerization, 24
- MHV-68. *See* Murine herpesvirus-68
- MicA, small RNA regulator function, 219–220
- MicroRNA, viral function, 172–174
- Modules, RNA
 - crystal structure comparisons, 315–316
 - examples, 313
 - large assembly modeling, 313
 - searching, 312–313
- Montmorillonite, nucleoside 5'-phosphorimidazole
 - polymerization, 24
- mRNA
 - splicing. *See* Spliceosome
 - translation. *See* Ribosome
- MSUD. *See* Meiotic silencing of unpaired DNA
- Murine herpesvirus-68 (MHV-68), noncoding RNA, 175

N

- NAD/P
 - abiotic synthesis of NAD, 46
 - continuity with RNA world, 47–48
 - initial darwinian ancestor modern descendant, 45–47
 - replication chemistry, 48–49
- NEAT* RNAs, cell structure integrity role, 288
- NMR. *See* Nuclear magnetic resonance
- NRON*, transcription factor mediation, 287
- NS3, helicase mechanism studies, 328
- Nuclear magnetic resonance (NMR), ligand-induced
 - conformational change studies in riboswitches, 86
- Nucleolin, Epstein-Barr virus-encoded RNA binding, 170
- Nucleoside 5'-phosphorimidazoles, polymerization, 23–24

Nucleotides

- abiotic synthesis, 32–35
- activation in polymerization, 20–21, 25, 32
- synthetic ribozymes, 31–32

O

- OmrB, small RNA regulator function, 219–220
- OmtA, small RNA regulator function, 219–220
- Optical tweezers
 - force measurements, 322–323
 - ribosome-mRNA movement studies, 328–329
- OxyS, small RNA regulator function, 219–220

P

- P15AS*, DNA methylation mediation, 285
- PABPC1. *See* Poly(A)-binding protein C1
- PAN RNA. *See* Polyadenylated nuclear RNA
- PCR. *See* Polymerase chain reaction
- Peptide nucleic acid (PNA)
 - abiotic synthesis, 37
 - polymer structure, 36
- Peptidyl transferase center. *See* Ribosome
- Perchlorate, solar system distribution, 15
- PEV. *See* Position effect variegation
- Phosphoramidate nucleic acids, cellular life origins, 57–59
- 5-Phosphoribosyl-1-pyrophosphate (PRPP), ribozyme
 - synthesis limitations, 32
- piRNA, functions, 250–251, 258
- Piwi. *See* Argonaute
- PKR. *See* Protein kinase R
- PNA. *See* Peptide nucleic acid
- Poly(A)-binding protein C1 (PABPC1), PAN RNA
 - association, 172
- Polyadenylated nuclear (PAN) RNA, Kaposi's sarcoma-associated herpesvirus function, 172
- Polycomb proteins
 - long noncoding RNA advantages in regulation, 274–276
 - RNA recruitment, 272–274, 282
- Polymerase chain reaction (PCR), six letter polymerase
 - chain reaction, 15–16
- Position effect variegation (PEV), heterochromatin silencing, 256
- Pre-mRNA splicing. *See* Spliceosome
- Primordial RNA world, overview, 2–3
- p-RNA, structure, 35–36
- Protein kinase R (PKR), Epstein-Barr virus-encoded RNA
 - binding, 168
- Protein synthesis. *See also* Ribosome
 - duplicator RNA and origins of ribosomal decoding site, 148–150
 - evolutionary driving force for translation from RNA world, 150–151, 162–163
 - RNA role, 8, 10, 22, 126–127, 142–144, 157–158
 - stop tRNAs and type I release factor evolution, 148
 - translation steps, 156–157
- Protocell. *See* Cellular life
- Prp2, spliceosome function, 191

- Prp5
heterochromatic RNA interference at fission yeast centromeres, 260
spliceosome function, 190–191
- Prp8
heterochromatic RNA interference at fission yeast centromeres, 260
spliceosome function, 191, 195
- Prp10, heterochromatic RNA interference at fission yeast centromeres, 260
- Prp16, spliceosome function, 191
- Prp19, spliceosome function, 188, 191
- Prp22, spliceosome function, 191–192
- Prp28, spliceosome function, 191
- Prp43, spliceosome function, 192
- PRPP. *See* 5-Phosphoribosyl-1-pyrophosphate
- Pseudoknot
frameshifting studies, 325–326
telomerase RNA, 208–209
- R**
- R2 retrotransposon, RNA structure elucidation, 297–298
- RCNMV. *See* Red clover necrotic mosaic virus
- Rdp1, heterochromatic RNA interference at fission yeast centromeres, 259
- Red clover necrotic mosaic virus (RCNMV), noncoding RNA, 175
- Release factors, stop tRNAs and type I release factor evolution, 148
- Release factors, tRNA mimics, 129–130
- RepA
Polycomb protein recruitment, 274–275
signal sensing, 288
X-chromosome inactivation role, 269–270
- Ribose, instability, 12
- Ribosome. *See also* Protein synthesis
aminoacyl-tRNA selection, 144–146
antibiotic inhibition of peptidyl transferase reaction, 130–133
complexes with both A- and P-site substrates bound, 127–128
crystal structures, 125–126, 156
duplicator RNA and origins of ribosomal decoding site, 148–150
elongation factor structure and function, 136–137
evolutionary driving force for translation from RNA world, 150–152, 162–163
fidelity of translation, 133
induced-fit activation of peptide synthesis, 128–129
mRNA movement studies with optical tweezers, 328–329
peptidyl transferase center
metal ions, 128
peptide bond formation mechanism, 126–127, 160
peptide release, 160–161
ribozyme activity, 143–144, 157–158
RNA components, 126
peptidyl-tRNA protection from hydrolysis, 128–129
protein structures and functions, 148
pseudoknot frameshifting studies, 325–326
release factors as tRNA mimics, 129–130
rRNA
role in mRNA decoding, 134–136
tRNA interactions in P site, 146–147
subunits and functions, 124–125
transition state intermediate and stabilization, 128
translation steps, 156–157
translocation
E site conservation and role, 162
RNA molecular mechanics, 147
subunit interactions, 161–162
tRNA energy storage, 162
tRNA
binding sites in small ribosomal subunit, 133–134
CCA end binding to E site of large subunit, 130
decoding
evolutionary role of minor groove recognition, 158–159
minor groove recognition by RNA, 158
structural changes, 159
dynamics analysis with fluorescence resonance energy transfer, 329
stop tRNAs and type I release factor evolution, 148
- Riboswitch
S-adenosylmethionine riboswitch, 69–71
classes, 64–65, 68–69
domains, 80
effector molecule recognition, 84–85
functional overview, 64, 80
gene regulation
mechanisms, 65–66, 80
temporal sensitivity, 86–87
ligand binding affinity and kinetics of function, 67–68
origins, 75
ribozyme control mechanisms, 67
RNA world functions, 89
small RNA regulators, 221
structure
examples, 80–82
folding pathways of purine riboswitch aptamer, 82–84
ligand-induced conformational change, 85–86
models for structural switching, 87–89
tandem switches, 71–75
- RIG-I, helicase mechanism studies, 328
- RITS. *See* RNA-induced initiation of transcriptional silencing complex
- RNA III, small RNA regulator function, 221
- RNAi. *See* RNA interference
- RNA-induced initiation of transcriptional silencing complex (RITS), heterochromatic RNA interference at fission yeast centromeres, 259–260
- RNA interference (RNAi). *See also* Argonaute
CRISPR homology, 238–240
eukaryote distribution, 257
heterochromatic RNA interference
filamentous fungi, 262–263
fission yeast centromeres, 258–261
silencing on chromosome arms, 261–262

- RNA interference (RNAi) (*Continued*)
immune function, 250
mechanisms, 257–258
pest control applications, 350
screening in vivo
 Caenorhabditis elegans, 345–346
 developmental biology applications, 349
 Drosophila melanogaster, 346–349
 plants and crop improvement, 350
 reagents, 344–345
 vertebrate models, 349–350
therapeutic prospects, 350–351
- RNA ligase ribozyme
magnesium dependence, 30
polymerization reaction and optimization, 30
structures, 29–30
- RNA polymerase II
heterochromatic RNA interference at fission yeast centromeres, 260
long noncoding RNA mediation of loading, 285–287
- RNA–protein complexes, modeling, 313
- RNA replicase ribozyme
accuracy and survival, 26–27
cellular life origins, 56–57
chicken-and-egg paradox, 27–29
ligase evolution, 29–31
RNA–first view of life, 25
- RNA technology, as third RNA world, 4
- RprA, small RNA regulator function, 219–220
- rRNA. *See* Ribosome
- RybB, small RNA regulator function, 219–220
- RyhB, small RNA regulator function, 219–220
- S**
- SAH. *See* S-Adenosylhomocysteine
- SAM. *See* S-Adenosylmethionine
- Secondary structure, RNA
comparative sequence analysis
 automation
 align then fold approach, 300
 fold and align approach, 299
 fold then align approach, 300
 programs, 300
 overview, 311–312
crystal structure comparisons, 315–316
evolution studies, 302–304
folding space restraints
 combined methods for determination, 297–298
 comparative structures, 297
 experimental findings, 296–297
 overview, 295–296
free energy minimization, 294
functional RNA discovery, 300–301
overview of analysis, 310–311
partition functions and probabilities, 294–295
phylogenetic reconstruction, 303
prediction programs, 295
prospects for study, 301–302
- SELEX
clinical applications of aptamers, 334–335
historical perspective, 334–335
proteomics for aptamer optimization, 335–336
RNA function discovery, 338–339
RNA world applications of aptamers, 337–338
- SOMAmers
plasma proteome probing at high throughput and specificity, 337
specificity, 336
structure, 336
- SF1, spliceosome function, 190
- SF3 proteins, spliceosome function, 188, 190
- SgrS, small RNA regulator function, 221
- Six letter polymerase chain reaction, 15–17
- Small nuclear ribonucleoproteins (snRNPs), spliceosome structures
electron microscopy, 193–194, 197–199
high-resolution structures, 194–195
U1 small nuclear ribonucleoprotein, 195–196
- Small RNA regulators. *See* Bacterial small RNA regulators; CRISPRs
- Small self-cleaving ribozymes
active site mechanisms, 96
glmS ribozyme, 98–99
hairpin ribozyme, 96–98
hammerhead ribozyme, 98
hepatitis delta virus ribozyme, 99–100
internal transesterification reaction, 94–95
structural overview, 95–96
- snRNPs. *See* Small nuclear ribonucleoproteins
- SOMAmers
plasma proteome probing at high throughput and specificity, 337
specificity, 336
structure, 336
- Spliceosome
cis-acting elements and catalytic steps of splicing, 182–184
conformational two-state model for catalytic center, 187
intron- and exon-defined assembly pathways, 183, 185
overview of pre-mRNA splicing, 182
protein
 composition dynamics, 187–189
 flexibility of metazoan spliceosomes, 189–190
 posttranslational modifications, 192–193
 RNA footprinting studies, 197
 splice site recognition role, 190
 structural rearrangement facilitation, 190–192
RNA–RNA interactions, 185–187
small nuclear ribonucleoprotein structures
 electron microscopy, 193–194, 197–199
 high-resolution structures, 194–195
 U1 small nuclear ribonucleoprotein, 195–196
 U2-dependent spliceosome mechanism, 183–184
- SRA, histone modification mediation, 283
- SreA, small RNA regulator function, 221
- SreB, small RNA regulator function, 221
- sRNAs. *See* Bacterial small RNA regulators
- Sub2, spliceosome function, 190–191
- SUNH4/KYP, heterochromatic RNA interference, 262
- Sutherland's synthesis, prebiotic origins of RNA, 13

Systematic evolution of ligands by exponential enrichment.
See SELEX; SOMAmers

T

Targetron, group II intron, 116

Telomerase

evolutionary origins of components, 211–212

functional overview, 206

protein and RNA component interplay, 206, 210

RNA

evolutionary divergence, 206–207

fine-tuning of repeat synthesis activity, 209–210

holoenzyme biogenesis and regulation motifs, 210–211

motif gain-of-function in ribonucleoprotein context, 212

nuclear assembly and addressing in vertebrates, 211

pseudoknot, 208–209

stem terminus element, 209

template 5'-boundary enforcement, 210

template, 207–208

TERT-binding motifs, 210

yeast function, 211

Template-directed replication

multi-stem-loops structures, 28

nonenzymatic replication of RNA, 24–25

TER. *See* Telomerase

Tertiary structure, RNA

constraint extraction, 312

crystal structure comparisons, 315–316

large assembly modeling, 313

Thiamin pyrophosphate (TPP), riboswitch ligand, 66–67,
85, 86

Thioester peptide nucleic acid (tPNA)

abiotic synthesis, 37

polymer structure, 36–37

4-Thiouridylate, ribozyme synthesis, 31–32

Threose

instability, 12

ribose substitution, 15

threose nucleotide polymers, 35–36

tmRNA, functions, 223–224

tPNA. *See* Thioester peptide nucleic acid

TPP. *See* Thiamin pyrophosphate

Translation. *See* Protein synthesis; Ribosome

tRNA. *See* Ribosome

Tsix

Polycomb protein binding, 274

signal sensing, 288

X-chromosome inactivation role, 270–272

U

Unnatural nucleic acids, potential in RNA world,
15–16

V

Vascular endothelial growth factor (VEGF), Macugen
inhibition, 334

VEGF. *See* Vascular endothelial growth factor

Vesicle. *See* Membrane

Viral noncoding RNA

adenovirus, 166, 169

cytomegalovirus, 174

Epstein-Barr virus, 166, 168, 170, 174–175

herpes simplex virus-1, 174

herpesvirus saimiri, 170–171

Kaposi's sarcoma-associated herpesvirus, 171–172

microRNAs, 172–174

murine herpesvirus-68, 175

overview, 166–168

prospects for study, 175

red clover necrotic mosaic virus, 175

West Nile virus, 175

W

West Nile virus (WNV), noncoding RNA, 175

WNV. *See* West Nile virus

Work, Gibbs free energy change, 323

X

X-chromosome inactivation (XCI)

long noncoding RNA advantages, 274–276

noncoding RNA regulators, 269–270

overview, 268

RNA in pairing, counting, and choice,
270–272

signal sensing by RNA, 288

symmetry break by Tsix RNA, 272

unique features, 268–269

XCI. *See* X-chromosome inactivation

Xist

Polycomb protein regulation, 272–274

signal sensing, 288

X-chromosome inactivation role,
269–270

Xite, X-chromosome inactivation role, 271

The RNA Worlds in Context

Thomas R. Cech

Department of Chemistry and Biochemistry, Howard Hughes Medical Institute, University of Colorado, Boulder,
Colorado 80309-0215

Correspondence: thomas.cech@colorado.edu

SUMMARY

The chapters in this collection discuss not one RNA world, but two. The first is the primordial RNA world, a hypothetical era when RNA served as both information and function, both genotype and phenotype. The second RNA world is that of today's biological systems, where RNA plays active roles in catalyzing biochemical reactions, in translating mRNA into proteins, in regulating gene expression, and in the constant battle between infectious agents trying to subvert host defense systems and host cells protecting themselves from infection. This second RNA world is not at all hypothetical, and although we do not have all the answers about how it works, we have the tools to continue our interrogation of this world and refine our understanding. The fun comes when we try to use our secure knowledge of the modern RNA world to infer what the primordial RNA world might have looked like.

Outline

- | | |
|------------------------------|---|
| 1 The primordial RNA world | 3 The world of RNA technology and
medical applications |
| 2 The contemporary RNA world | References |

1 THE PRIMORDIAL RNA WORLD

The term “RNA world” was first coined by Gilbert (1986), who was mainly interested in how catalytic RNA might have given rise to the exon–intron structure of genes. But the concept of RNA as a primordial molecule is older, hypothesized by Crick (1968), Orgel (1968), and Woese (1967). Noller subsequently provided evidence that ribosomal RNA is more important than ribosomal proteins for the function of the ribosome, giving experimental support to these earlier speculations (Noller and Chaires 1972; Noller 1993). The discovery of RNA catalysis (Kruger et al. 1982; Guerrier-Takada et al. 1983) provided a much firmer basis for the plausibility of an RNA world, and speculation was rekindled. The ability to find a broad range of RNA catalysts by selection of RNAs from large random-sequence libraries (SELEX) (Ellington and Szostak 1990; Tuerk and Gold 1990; Wright and Joyce 1997) fueled the enthusiasm, and made it possible to conceive of a ribo-organism that carried out complex metabolism (Benner et al. 1989). The widely accepted order of events for the evolution of an RNA world and from the RNA world to contemporary biology is summarized in Figure 1.

Did an RNA world exist? Some of the most persuasive arguments in favor of an RNA world are as follows. First, RNA is both an informational molecule and a biocatalyst—both genotype and phenotype—whereas protein has extremely limited ability to transmit information (as with prions). Thus, RNA should be capable of replicating




Figure 1. An RNA world model for the successive appearance of RNA, proteins, and DNA during the evolution of life on Earth. Many isolated mixtures of complex organic molecules failed to achieve self-replication, and therefore died out (indicated by the arrows leading to extinction.) The pathway that led to self-replicating RNA has been preserved in its modern descendants. Multiple arrows to the left of self-replicating RNA cover the likely self-replicating systems that preceded RNA. Proteins large enough to self-fold and have useful activities came about only after RNA was available to catalyze peptide ligation or amino acid polymerization, although amino acids and short peptides were present in the mixtures at far left. DNA took over the role of genome more recently, although still >1 billion years ago. LUCA (Last Universal Common Ancestor) already had a DNA genome and carried out biocatalysis using protein enzymes as well as RNP enzymes (such as the ribosome) and ribozymes.

itself, and indeed RNA can perform the sort of chemistry required for RNA replication (Cech 1986). Second, it is more parsimonious to conceive of a single type of molecule replicating itself than to posit that two different molecules (such as a nucleic acid and a protein capable of replicating that nucleic acid) were synthesized by random chemical reactions in the same place at the same time. Third, the ribosome uses RNA catalysis to perform the key activity of protein synthesis in all extant organisms, so it must have done so in the Last Universal Common Ancestor (LUCA). Fourth, other catalytic activities of RNA—activities that RNA would need in an RNA world but that have not been found in contemporary RNAs—are generally already present in large combinatorial libraries of RNA sequences and can be discovered by SELEX. Fifth, RNA clearly preceded DNA, because multiple enzymes are dedicated to the biosynthesis of the ribonucleotide precursors of RNA, whereas deoxyribonucleotide biosynthesis is derivative of ribonucleotide synthesis, requiring only two additional enzymatic activities (thymidylate synthase and ribonucleotide reductase.) Finally, a primordial RNA world has the attractive feature of continuity; it could evolve into contemporary biology by the sort of events that are well predated, whereas it is unclear how a self-replicating system based on completely unrelated chemistry could have been supplanted by RNA.

Opinions vary, however, as to whether RNA comprised the first autonomous self-replicating system or was a derivative of an earlier system. Benner et al. (this collection) and Robertson and Joyce (this collection) are circumspect, noting that the complexity and the chiral purity of modern RNA create challenges for thinking about it arising *de novo*. On the other hand, the recent finding that activated pyrimidine ribonucleotides can be synthesized under plausible prebiotic conditions (Powner et al. 2009) means that it is premature to dismiss the RNA-first scenarios. Yarus (this collection), an unabashed enthusiast for an RNA world, argues for a closely related replicative precursor. In vitro evolution studies directed towards an RNA replicase ribozyme continue apace and are of great importance in establishing the biochemical plausibility of RNA-catalyzed RNA replication (Johnston et al. 2001; Zaher and Unrau 2007; Lincoln and Joyce 2009; Shechner et al. 2009).

What might the first ribo-organism have looked like? Schrum et al. (this collection) describe progress in achieving replication of simple nucleic acid-like polymers within lipid envelopes, thereby constituting “protocells.” These liposomes can grow and upon agitation can divide to give daughter protocells, carrying newly replicated nucleic acids. Whether by lipids or other means, some form of encapsulation must have been a key early step in life. Encapsulation can protect the genome from degradation and

predation, allows useful small molecules to be concentrated for the cell's use, and enables natural selection by ensuring that the benefit of newly derived functions accrues to the organism that stumbled across them.

2 THE CONTEMPORARY RNA WORLD

Today, RNA is the central molecule in gene expression in all extant life, serving as the messenger. It is also central to biocatalysis, seen dramatically in the ribosome but also in ribozymes and RNPzymes such as telomerase and the signal recognition particle. More recently, its diverse roles in regulation of (DNA) gene expression have been discovered. It is useful to organize the discussion of contemporary RNA activities as a spectrum, going from those activities that are so RNA-centered that one could conceive of them having operated in a primordial RNA world very much as they do today, to those that rely more and more on collaboration with proteins, to those RNAs that work on DNA (Fig. 1).

What can RNA do by itself? It can bind small metabolites (such as guanine, S-adenosylmethionine, and lysine) with exquisite specificity, and then use this binding energy to switch from one RNA structure to another. These riboswitches are common regulators of gene expression in Gram-positive bacteria, and are also found in other organisms including plants (Breaker [this collection]; Garst et al. [this collection]). Furthermore, even very small RNAs can act as ribozymes, accomplishing sequence-specific self-cleavage (Ferré-D'Amaré and Scott [this collection]). These self-cleavers can be easily re-engineered into multiple-turnover RNA-cleaving enzymes, so it is straightforward to imagine that they could have served such a function in a primordial RNA world. Larger ribozymes can accomplish sophisticated RNA splicing reactions, as described for group II introns by Lambowitz and Zimmerly (this collection). There are a number of similarities, both mechanistic and structural, between group II intron self-splicing and spliceosomal splicing of mRNA introns, providing a plausible continuum from the RNA world to post-protein contemporary biology.

Although RNA can perform many activities by itself, in modern cells RNA more often works in concert with proteins. The ribosome uses both RNA and protein to catalyze message-encoded protein synthesis. Yet the heart of the peptidyl transferase center is a ribozyme, and other fundamental activities such as mRNA start-site selection, codon–anticodon interaction, and decoding involve direct RNA–RNA interactions, so the RNA world ancestry of the ribosome is apparent (Moore and Steitz, Noller, Ramakrishnan [all in this collection]). The same can be said of the spliceosome (Will and Lührmann [this collection]).

Although a detectable level of catalysis of an isolated step of RNA splicing can be achieved with pure snRNAs (Valadkhan et al. 2009), the efficient and regulated splicing of an entire genome's collection of primary transcripts requires the collaboration of almost 200 proteins and five snRNAs in the modern spliceosome. Telomerase represents another paradigm, as it includes a canonical protein enzyme (TERT) that operates in intimate collaboration with RNA (Blackburn and Collins [this collection])—so it appears to derive from more recent evolution, after protein enzymes and DNA chromosomes were well established.

It seems likely that the most recently evolved functions of RNA involve regulation of DNA—because there would have been no DNA to regulate in a primordial RNA world! Nevertheless, similar principles could have been active in an RNA world. Gottesman and Storz (this collection) describe RNA regulation in bacteria, which occurs through a range of mechanisms ranging from the simple “antisense RNA” principle of inhibition by complementary base-pairing to RNA–protein interactions. In eukaryotes, several classes of noncoding RNAs perform diverse functions in the regulation of gene expression. Small double-stranded RNAs (for example, the 21-bp small-interfering RNAs and the microRNAs) regulate the stability or the translatability of mRNAs (Joshua-Tor and Hannon [this collection]). Here the RNA provides such a simple function—recognition of complementary sequences on the mRNA target—that the authors choose to organize their discussion according to subfamilies of the Argonaute proteins that bind the small RNAs. The RNA interference (RNAi) pathway is involved not only in mRNA-level events, but also in the regulation of chromatin structure as described by Volpe and Martienssen (this collection). Maintenance of the highly condensed heterochromatin found at chromosome centromeres depends on this RNAi activity. Finally, long noncoding RNAs usually acting *in cis* (on the chromosome or the local region where they were synthesized) can turn off gene expression by attracting proteins that modify chromatin structure. The effect can spread to an entire chromosome, in the case of the Xist RNA that condenses one of the two X chromosomes in female mammals and thereby gives gene dosage compensation (Lee [this collection]). In other cases, the effect is more local, affecting transcription of a single gene or a group of genes (Wang et al. [this collection]). These recently discovered activities of RNA show that the RNA world never stopped (and has not stopped) evolving.

Diverse viral encoded ncRNAs are used as weapons either to circumvent host defense or otherwise manipulate host cellular machinery for their own purposes (Steitz et al. [this collection]). Although several of the classes of viral

ncRNAs are counterparts of cellular equivalents, some are distinctive. Bacteria have evolved the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) defense system to protect themselves from alien DNA such as that injected by bacteriophages (Wang et al. [this collection]). Here, the information identifying the invading genome is stored in the form of DNA, but it is subsequently converted to small guide RNAs that recognize and interfere with subsequent invaders. Although there is a clear analogy between CRISPR and eukaryotic RNAi, the two systems appear to have evolved completely independently.

3 THE WORLD OF RNA TECHNOLOGY AND MEDICAL APPLICATIONS

I oversimplified when I said that there were two RNA worlds. There is in fact a third—the world of RNA research and development. This third RNA world should be of special interest to students, because this RNA world offers opportunities for gainful employment!

RNA function depends on its structure—it is the seemingly limitless variety of structures that allows so many diverse functions. We can now predict RNA secondary structure quite well (Mathews et al. [this collection]) and see much progress on predicting 3D structure (Westhof et al. [this collection]). Remarkably, we can now watch molecules of RNA fold and unfold and switch from one state to another in “single-molecule experiments” (Tinoco et al. [this collection]). We can use double-stranded RNAs and the intrinsic RNAi machinery present in organisms to do genome-wide knock-downs of gene function (Perrimon et al. [this collection]). Finally, RNA science is poised to make an impact on medicine. For example, aptamers can monitor the concentrations of many of the proteins in human serum, which has diagnostic applications because the presence of many proteins is correlated with health and disease (Gold et al. [this collection]). In addition, both microRNAs and antisense nucleic acids that inhibit miRNAs have pharmaceutical potential, which is under development in numerous biotechnology and pharmaceutical companies.

Thus, the authors of this collection take us on a fascinating journey through three RNA worlds. The primordial RNA world (ca. four billion years ago) relied on the dual ability of RNA to serve as both informational molecule and biocatalyst, providing a self-replicating system. Coupled with other ribozymes that carried out complex metabolism and encapsulated in some sort of envelope, self-replicating RNA constituted an early life form that was the ancestor of contemporary biology. The second RNA world is that of contemporary biology, where RNA occasionally acts by itself (ribozymes and riboswitches) but more often acts in

concert with proteins. The ribosome and the spliceosome still “remember” their ribozyme heritage, whereas telomerase and the signal recognition particle have moved on to incorporate canonical protein enzymes. The RNA interference system and CRISPR have gone further, reducing the role of the RNA to that of a simple guide sequence. Finally, the third RNA world—that of RNA technology and medical applications—is a baby compared to even the second RNA world, because it arose only in the past half-century. Although this last RNA world is only perhaps one millionth of one per cent as old as the primordial RNA world, it is a vibrant community, and my co-editors John Atkins and Ray Gesteland and I feel privileged to be part of it.

REFERENCES

- Benner SA, Ellington AD, Tauer A. 1989. Modern metabolism as a palimpsest of the RNA world. *Proc Natl Acad Sci* **86**: 7054–7058.
- Benner SA, Kim H-J Yang Z. 2010. Setting the Stage: The history, chemistry, and geobiology behind RNA. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003541.
- Blackburn EH, Collins K. 2010. Telomerase: An RNP enzyme synthesizes DNA. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003558.
- Breaker RR. 2010. Riboswitches and the RNA world. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003566.
- Cech TR. 1986. A model for the RNA-catalyzed replication of RNA. *Proc Natl Acad Sci* **83**: 4360–4363.
- Crick FH. 1968. The origin of the genetic code. *J Mol Biol* **38**: 367–379.
- Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. *Nature* **346**: 818–822.
- Ferré-D’Amaré AR, Scott WG. 2010. Small self-cleaving ribozymes. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003574.
- Garst AD, Edwards AL, Batey RT. 2010. Riboswitches: Structures and mechanisms. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003533.
- Gilbert W. 1986. Origin of life: The RNA world. *Nature* **319**: 618.
- Gold L, Janjic N, Jarvis T, Schneider D, Walker JJ, Wilcox SK, Zichi D. 2010. Aptamers and the RNA world, past and present. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003582.
- Gottesman S, Storz G. 2010. Bacterial small RNA regulators: Versatile roles and rapidly evolving variations. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003798.
- Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S. 1983. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. *Cell* **35**: 849–857.
- Johnston WK, Unrau PJ, Lawrence MS, Glasner ME, Bartel DP. 2001. RNA-catalyzed RNA polymerization: Accurate and general RNA-templated primer extension. *Science* **292**: 1319–1325.
- Joshua-Tor L, Hannon GJ. 2010. Ancestral roles of small RNAs: An agocentric perspective. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003772.
- Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR. 1982. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of *Tetrahymena*. *Cell* **31**: 147–157.
- Lambowitz AM, Zimmerly S. 2010. Group II introns: Mobile ribozymes that invade DNA. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003616.
- Lee JT. 2010. The X as model for RNA’s niche in epigenomic regulation. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003749.

- Lincoln TA, Joyce GF. 2009. Self-sustained replication of an RNA enzyme. *Science* **323**: 1229–1232.
- Mathews DH, Moss WN, Turner DH. 2010. Folding and finding RNA secondary structure. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003665.
- Moore PB, Steitz TA. 2010. The roles of RNA in the synthesis of protein. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003780.
- Noller HF. 2010. Evolution of protein synthesis from an RNA world. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003681.
- Noller HF. 1993. Peptidyl transferase: Protein, ribonucleoprotein, or RNA? *J Bacteriol* **175**: 5297–5300.
- Noller HF, Chaires JB. 1972. Functional modification of 16S ribosomal RNA by kethoxal. *Proc Natl Acad Sci* **69**: 3115–3118.
- Orgel LE. 1968. Evolution of the genetic apparatus. *J Mol Biol* **38**: 381–393.
- Perrimon N, Ni J-Q, Perkins L. 2010. In vivo RNAi: Today and tomorrow. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003640.
- Powner MW, Gerland B, Sutherland JD. 2009. Synthesis of activated pyrimidine ribonucleotides in prebiotically plausible conditions. *Nature* **459**: 239–242.
- Ramakrishnan V. 2010. The ribosome: Some hard facts about its structure and hot air about its evolution. In *RNA Worlds* (eds. JF Atkins, RF Gesteland, TR Cech). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Robertson MP, Joyce GF. 2010. The origins of the RNA world. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003608.
- Schrum JP, Zhu TF, Szostak JW. 2010. The origins of cellular life. In *RNA Worlds* (eds. JF Atkins, RF Gesteland, TR Cech). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Shechner DM, Grant RA, Bagby SC, Koldobskaya Y, Piccirilli JA, Bartel DP. 2009. Crystal structure of the catalytic core of an RNA-polymerase ribozyme. *Science* **326**: 1271–1275.
- Steitz J, Borah S, Cazalla D, Fok V, Lytle R, Mitton-Fry R, Riley K, Samji T. 2010. Noncoding RNPs of viral origin. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a005165.
- Tinoco I, Chen G, Qu X. 2010. RNA reactions one molecule at a time. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003624.
- Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* **249**: 505–510.
- Valadkhan S, Mohammadi A, Jaladat Y, Geisler S. 2009. Protein-free small nuclear RNAs catalyze a two-step splicing reaction. *Proc Natl Acad Sci* **106**: 11901–11906.
- Volpe T, Martienssen RA. 2010. RNA interference and heterochromatin assembly. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003731.
- Wang X, Song X, Glass CK, Rosenfeld MG. 2010. The long arm of long noncoding RNAs: Roles as sensors regulating gene transcriptional programs. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003756.
- Westhof E, Masquida B, Jossinet F. 2010. Predicting and modeling RNA architecture. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003632.
- Will CL, Lührmann R. 2010. Spliceosome structure and function. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003707.
- Woese CR. 1967. The genetic code: The molecular basis for genetic expression. p. 186. Harper & Row.
- Wright MC, Joyce GF. 1997. Continuous in vitro evolution of catalytic function. *Science* **276**: 614–617.
- Yarus M. 2010. Getting past the RNA world: The initial Darwinian ancestor. *Cold Spring Harb Perspect Biol* doi: 10.1101/cshperspect.a003590.
- Zaher HS, Unrau PJ. 2007. Selection of an improved RNA polymerase ribozyme with superior extension and fidelity. *RNA* **13**: 1017–1026.